Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of September 2025. The report serves as a transaction notification regarding a specific equity award to a Person Discharging Managerial Responsibilities (PDMR) or Person Closely Associated (PCA).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a single corporate transaction.
| Metric | Value |
|---|---|
| Transaction Type | Award of Ordinary Shares under the 2025 Share Value Plan |
| Instrument | Ordinary shares of 31 1/4 pence each (ISIN: GB00BN7SWP63) |
| Volume | 10,050 shares |
| Price per Share | £14.4250 |
| Transaction Date | September 02, 2025 |
Material Changes
The filing does not contain comparative financial data or material changes to the company's operational or financial status versus prior periods. It solely documents the issuance of shares to Victoria Whyte, SVP & Company Secretary.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document is a standard compliance notification for an equity award.
Key Facts for Investor Verification
- Recipient: Victoria Whyte, SVP & Company Secretary.
- Transaction Nature: Initial notification of an award under the 2025 Share Value Plan.
- Valuation: 10,050 shares awarded at a price of £14.4250 per share.
- Timing: Transaction executed on September 02, 2025; filed on September 04, 2025.
- Scope: This filing does not reflect broader company financial results.